EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau

Patricia Wongsodirdjo, Alayna C Caruso iD, Alicia K Yong iD, Madeleine A Lester, Laura J Vella, Ya Hui Hung, Rebecca M Nisbet iD

Brain Communications · 2024-03-01 · 6 (2)

DOI: 10.1093/braincomms/fcae100 ↗

At a glance

Journal article in Brain Communications, published online on 2024-03-25. Written by Patricia Wongsodirdjo and 6 co-authors. Institution: The Florey Institute, Parkville, Victoria 3052, Australia. Cited 20 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, Alzheimer’s Association Research, Victoria Research Acceleration.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Monoclonal antibodies have emerged as a leading therapeutic agent for the treatment of disease, including Alzheimer’s disease. In the last year, two anti-amyloid monoclonal antibodies, lecanemab and aducanumab, have been approved in the USA for the treatment of Alzheimer’s disease, whilst several tau-targeting monoclonal antibodies are currently in clinical trials. Such antibodies, however, are expensive and timely to produce and require frequent dosing regimens to ensure disease-modifying effects. Synthetic in vitro-transcribed messenger RNA encoding antibodies for endogenous protein expression holds the potential to overcome many of the limitations associated with protein antibody production. Here, we have generated synthetic in vitro-transcribed messenger RNA encoding a tau-specific antibody as a full-sized immunoglobulin and as a single-chain variable fragment. In vitro transfection of human neuroblastoma SH-SY5Y cells demonstrated the ability of the synthetic messenger RNA to be translated into a functional tau-specific antibody. Furthermore, we show that the translation of the tau-specific single-chain variable fragment as an intrabody results in the specific engagement of intracellular tau. This work highlights the utility of messenger RNA for the delivery of antibody therapeutics, including intrabodies, for the targeting of tau in Alzheimer’s disease and other tauopathies.

Subjects

Author keywords

Alzheimer’s diseaseantibodyimmunotherapymRNAtau

Authors and institutions

  • The Florey Institute, Parkville, Victoria 3052, Australia.
  • Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria 3052, Australia.
  • Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria 3052, Australia.

ORCID profiles: Alayna C Caruso, Alicia K Yong, Rebecca M Nisbet

Funding

  • National Health and Medical Research Council
  • Alzheimer’s Association Research
  • Victoria Research Acceleration
  • Percy Baxter Charitable Trust

Cite

APA

Wongsodirdjo, P., Caruso, A. C., Yong, A. K., Lester, M. A., Vella, L. J., Hung, Y. H., & Nisbet, R. M. (2024). Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau. Brain Communications, 6(2). https://doi.org/10.1093/braincomms/fcae100

Vancouver

Wongsodirdjo P, Caruso AC, Yong AK, Lester MA, Vella LJ, Hung YH, et al. Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau. Brain Communications. 2024;6(2). doi:10.1093/braincomms/fcae100

BibTeX
@article{Wongsodirdjo2024,
  author = {Wongsodirdjo, Patricia and Caruso, Alayna C and Yong, Alicia K and Lester, Madeleine A and Vella, Laura J and Hung, Ya Hui and Nisbet, Rebecca M},
  title = {Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau},
  journal = {Brain Communications},
  year = {2024},
  volume = {6},
  number = {2},
  doi = {10.1093/braincomms/fcae100}
}
Start for free →